CurtisAndrewLachowiezMD

Hematology/Oncology

Physician

Dr. Lachowiez is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239
Phone+1 503-494-5058

Fax+1 503-494-5065

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
University of Nebraska College of MedicineClass of 2015

PubMed

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.
Curtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters
Blood. 2024-12-26
Landscape of somatic mutations and clonal evolution in NUP98-rearranged adult acute myeloid leukaemia.
Candace Frerich, Peng Li, Philipp W Raess, Jennifer Dunlap, Curtis Lachowiez
British Journal of Haematology. 2024-12-19
Mutation- and MRD-informed treatments for transplant-ineligible patients.
Curtis A Lachowiez, Courtney D DiNardo
Hematology. American Society of Hematology. Education Program. 2024-12-06

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024October 24th, 2024
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid LeukemiaSeptember 9th, 2024
Determining the Optimal Frontline Treatment of AMLDecember 6th, 2021
Join now to see all